References

1. Ambrus Jr. JL. (2017) Sjogren's syndrome: New paradigms and areas for future research. Clin. Immunol., 182: 1-3. [PMID:28673862]

2. Anderson DR, Nabil H, Leonard JE, Newman RA, Reff ME, Rastetter WH. (1998) Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma. Patent number: US5843439. Assignee: Anderson DR, Nabil H, Leonard JE, Newman RA, Reff ME, Rastetter WH. Priority date: 13/11/1992. Publication date: 01/12/1998.

3. Anderson DR, Rastetter WH, Hanna N, Leonard JE, Newman RA, Reff ME. (1994) Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma. Patent number: WO1994011026. Assignee: Idec Pharma Corp. Priority date: 26/02/2015. Publication date: 26/05/1994.

4. Fehr T, Stussi G. (2012) ABO-incompatible kidney transplantation. Curr Opin Organ Transplant, 17 (4): 376-85. [PMID:22790072]

5. Macklin PS, Morris PJ, Knight SR. (2015) A systematic review of the use of rituximab as induction therapy in renal transplantation. Transplant Rev (Orlando), 29 (2): 103-8. [PMID:25555541]

6. Stein R, Qu Z, Chen S, Rosario A, Shi V, Hayes M, Horak ID, Hansen HJ, Goldenberg DM. (2004) Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma. Clin. Cancer Res., 10 (8): 2868-78. [PMID:15102696]

7. Verstappen GM, van Nimwegen JF, Vissink A, Kroese FGM, Bootsma H. (2017) The value of rituximab treatment in primary Sjögren's syndrome. Clin. Immunol., 182: 62-71. [PMID:28478105]